Immune-Onc Therapeutics

We’re thrilled to announce that the first patient has been dosed with IO-108 in our global Phase 1b/2 trial for first-line treatment of advanced hepatocellular carcinoma (HCC) in clinical collaboration with Roche. This milestone marks a major step forward in our mission to develop first-in-class therapies targeting myeloid cell inhibitory receptors to fight cancer. By partnering with Roche, we’re exploring how IO-108 can enhance current treatment approaches and improve outcomes for patients battling liver cancer. Learn more about this trial and our commitment to advancing immuno-oncology: https://bit.ly/4ihX9Op

What an incredible experience at #ASH2024! Immune-Onc Therapeutics was honored to present our latest data on IO-202, a first-in-class anti-LILRB4 antibody, in combination with azacitidine for #CMML. Our oral presentation highlighted the potential of IO-202 to transform the treatment landscape for CMML. The data presented at ASH is just the beginning — a key first step toward meaningful advancements for patients who have long-awaited better options. We’re so grateful to the patients, caregivers, and investigators who made this progress possible. Thank you to Dr. Gabriel Mannis, the American Society of Hematology, Lee Greenberger, Daniel Pollyea, and everyone who attended our presentation and engaged with us at the conference. Your support and collaboration fuel our mission to deliver breakthrough therapies for patients with limited treatment options. ICYMI, read the press release here: https://bit.ly/3OIEI8V #Hematology #BloodCancerResearch #Innovation #CancerTreatment

Today at #ASH2024, we presented compelling Phase 1b trial data on IO-202, a first-in-class anti-LILRB4 antibody, in combination with azacitidine. Highlights include: ?? 50% Complete Remission (CR) Rate ?? 66.7% Overall Response Rate (ORR) ?? Exceptional results in patients with high LILRB4 expression (CR: 83%; ORR: 100%) These results underscore IO-202’s potential to revolutionize #CMML treatment, offering new hope for patients with this rare and challenging disease. We’re very proud to share this progress with the hematology community and continue advancing innovative therapies for those in need. Learn more: https://bit.ly/3OIEI8V #ImmunoOncology #HematologyInnovation #BloodCancerResearch #Innovation #CancerTreatment

Don't miss our oral presentation at #ASH2024 this week! Immune-Onc Therapeutics will present important updates from our Phase 1b trial of IO-202, a first-in-class anti-LILRB4 antibody, in combination with azacitidine, for the treatment of chronic myelomonocytic leukemia (CMML). ?? Date: December 9, 2024 ? Presentation Time: 5:45 PM PT ?? Location: Grand Hyatt San Diego, Grand Hall D ?? Session 637: Myelodysplastic Syndromes: Clinical and Epidemiological—Defining and Treating Chronic Myelomonocytic Leukemia ???? Presenter: Gabriel N. Mannis, M.D. Learn more about the potential of IO-202 to transform CMML treatment and address critical unmet needs. Heading to #ASH2024? Let’s connect! #ImmunoOncology #BloodCancerResearch #Innovation #CancerTreatment

We’re honored to be featured in the latest The Leukemia & Lymphoma Society (LLS) announcement, highlighting our work as part of their Therapy Acceleration Program (TAP). This program supports innovative approaches to address hard-to-treat blood cancers. Immune-Onc is proud to contribute to this important work with our Phase 1b Study of IO-202 in Chronic Myelomonocytic Leukemia (#CMML). We’re also looking forward to sharing important updates on this study at the upcoming American Society of Hematology Annual Meeting. Read the LLS announcement here: https://bit.ly/3Oqvvly Heading to #ASH2024? Let’s connect! #ImmunoOncology #BloodCancerResearch #LLS #Innovation #CancerTreatment

We're proud to announce that our Phase 1 dose escalation study results for IO-108 have been published in the Journal for ImmunoTherapy of Cancer (JITC). The study IO-108 is well tolerated and has led to objective responses as monotherapy and in combination with pembrolizumab. Among the highlights: - A durable complete response with IO-108 monotherapy in a patient with treatment-refractory #Merkel cell carcinoma lasting over 2 years - Pharmacodynamic changes in the monotherapy cohort provide proof of concept that targeting myeloid-suppressive pathways through LILRB2 inhibition may potentiate the clinical efficacy of anti-PD-1 immune checkpoint inhibitors - IO-108 + pembrolizumab combination therapy results in impressive efficacy (23% objective response rate) and all responding patients have microsatellite-stable (MSS) cancers that typically don't respond to immune checkpoint inhibitors These results reinforce the potential of IO-108 as a versatile therapeutic option. Learn more about our exciting progress here: https://bit.ly/4fu6e5N ? #ImmunoOncology #CancerResearch

Great News! Immune-Onc has been selected for an oral presentation at the 2024 ASH Annual Meeting to showcase new data from our Phase 1b study of IO-202 in chronic myelomonocytic leukemia (CMML). Join us to learn about the potential of IO-202, our novel anti-LILRB4 antibody, and see how we’re working to redefine treatment options for CMML patients. Learn more here: https://bit.ly/40sNUW4 #ASH24 #BloodResearch #hematology #biotech #CMML

This past week, Ahmed Aribi of the City of Hope and our #LLSTAP partner Lore Gruenbaum, joined by our CEO, Charlene Liao, attended #EHA2024, where we presented our latest data on IO-202 in chronic myelomonocytic leukemia (#CMML). Discussing our presentation, exchanging ideas, and exploring future collaborations were truly the highlights—a big thank you to everyone who attended our presentation and engaged with us. ? We look forward to continuing these important conversations as we advance a registrational study of IO-202 in frontline CMML patients.

New from Immune-Onc Therapeutics at #EHA2024! Today, we will present additional positive interim Phase 1b expansion cohort data for IO-202 in patients with chronic myelomonocytic leukemia (#CMML).??The study shows early and sustained complete remissions among CMML patients, regardless of their prognosis or mutation status. Learn more: https://lnkd.in/gZgdrvr6

#News: We look forward to presenting interim clinical data from our Phase 1b trial of IO-202 for the treatment of chronic myelomonocytic leukemia (#CMML) at the upcoming #EHA2024 Congress. View the press release for details: https://lnkd.in/gqnigH2w